HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study Sept. 9, 2026 -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101- EA-001) as "safe to proceed". The FDA det

Financing led by the Angelini Lumira Biosciences Fund supports development of first-in-class medicines targeting neuronal hyperexcitability and expands Navion’s AI-enabled NaViGATion™ discovery platform Navion Neurosciences, Inc., a preclinical-stage biotechnology company developing next-generation, precision sodium channel therapeutics for neurological diseases, today announced the $10.8M first closing of a Seed financing, led by the Angelini Lumira Biosciences Fund with participation from 3B

Development program will support inhaled formulation development and device assessment for Aceso's ACT-101 candidate, reinforcing Aptar Pharma's upstream services capabilities in inhaled biologic development Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a biotech developing novel therapies for cystic fibrosis (CF), a rare genetic disease, to advance the development of ACT-101, an antisense o

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. SKB378/WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbati

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026 Financing led by RA Capital Management, joined by Canaan Partners, Forbion, and other investors Sept. 09, 2026 -- Solstice Oncology, a clinical-stage immuno-oncology company focused on treating c

First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions Sept. 8, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study Sept. 09, 2026 -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharm

Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology Dr. Stephen Djedjos appointed Senior Vice President, Clinical Development Moonwalk Biosciences , a biotechnology company developing first-in-class

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

Phase 1 study evaluates distinct 225Ac and 177Lu compounds in breast cancer and other solid tumors; data expected in late 2027 225Ac-A9-0642 is the first actinium-based GRPR-targeting compound to enter clinical evaluation with the potential to deliver enhanced efficacy compared to first-generation 177Lu approaches 177Lu-A9-0631 is a lutetium-based GRPR-targeting compound with best-in-class potential Alpha-9 takes a modular approach to molecular engineering, holistically optimizing each component